MOREPENLAB
Morepen Labs
Each stock's 10,000-path forecast, rendered as light.
Morepen Labs (MOREPENLAB) Stock Analysis & Case Study
Is MOREPENLAB a good buy? The data-driven verdict.
Morepen Labs (MOREPENLAB) trades at ₹50,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 28/100.
On the numbers, Morepen Labs (MOREPENLAB) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing premium at 36.8× earnings, ROE of 6.2%, a 36% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
MOREPENLAB fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is MOREPENLAB overvalued? MOREPENLAB P/E vs its sector
MOREPENLAB's P/E of 36.8× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.40% dividend yield is below the peer median of 1.65%.
MOREPENLAB share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of MOREPENLAB history (-5%/yr drift, 49%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MOREPENLAB 2027 | ₹22 | ₹42 | ₹79 | -16% |
| MOREPENLAB 2028 | ₹14 | ₹35 | ₹87 | -30% |
| MOREPENLAB 2029 | ₹10 | ₹29 | ₹87 | -41% |
| MOREPENLAB 2030 | ₹7 | ₹25 | ₹88 | -50% |
| MOREPENLAB 2031 | ₹5 | ₹21 | ₹83 | -58% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MOREPENLAB goes up, or doubles?
The bull case for MOREPENLAB
- Morepen Labs is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹87.
The bear case & risks
- At 36.8× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.
- Return on equity is a soft 6.2%, capital efficiency trails higher-quality peers.
- The probability model is cautious 12 months out, only a 36% chance of finishing above today's price.
- High historical volatility (49%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹10.
MOREPENLAB volatility & expected range, how bumpy is the ride?
Over the last 2.0 years MOREPENLAB compounded at -5%/year with annualized volatility of 49%. That volatility implies a 1-year 80% range of ₹22–₹79, the honest backbone behind any single price target.
MOREPENLAB price forecast, the full 60-month probability fan
MOREPENLAB price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MOREPENLAB hits common targets within the simulated horizon?
Full multi-horizon detail on the MOREPENLAB price target & forecast page.
MOREPENLAB Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. MOREPENLAB scores 4/9,mixed financial health.
MOREPENLAB MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy MOREPENLAB with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 37.6% | 2.7× |
| ZerodhaCHEAPEST | 37.6% | 2.7× |
| Dhan | 40.0% | 2.5× |
Compare every broker on the MOREPENLAB MTF page.
MOREPENLAB vs peers,sector comparison
About Morepen Labs: sector, index & market-cap context
Morepen Labs (MOREPENLAB) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹2,743 Cr. See more Nifty 500 stocks.
How the MOREPENLAB Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Morepen Labs's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MOREPENLAB analysis, FAQs
Is Morepen Labs (MOREPENLAB) a good buy?
On the numbers, Morepen Labs (MOREPENLAB) high-risk on the numbers, a Downstox Snapshot Score of 28/100, weighing premium at 36.8× earnings, ROE of 6.2%, a 36% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MOREPENLAB overvalued or undervalued?
MOREPENLAB trades at 36.8× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the MOREPENLAB share price target for 2031?
MOREPENLAB's probability-weighted 2031 median target is ₹21, with an 80% range of ₹5–₹83 (10,000-path Monte-Carlo).
What is the probability MOREPENLAB doubles in 5 years?
The modelled probability of MOREPENLAB reaching ₹99 (2×) within 5 years is 8%.
What is the bull case for MOREPENLAB?
Morepen Labs is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in MOREPENLAB?
At 36.8× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished. Return on equity is a soft 6.2%, capital efficiency trails higher-quality peers. The probability model is cautious 12 months out, only a 36% chance of finishing above today's price.